AVTX insider buying and SEC filings, explained
Avalo Therapeutics, Inc. · CIK 1534120
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Cerecor Inc.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$215K
Planned sales (10b5-1)
$8.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 16, 2026 | Planned (10b5-1) | Christopher Ryan Sullivan (CFO) sold 12,394 shares at $16.33 ($202K), marked as a 10b5-1 plan trade. Holdings down 24% to 39,900 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 10, 2026 | Planned (10b5-1) | Christopher Ryan Sullivan (CFO) sold 10,185 shares at $17.62 ($179K), marked as a 10b5-1 plan trade. Holdings down 20% to 39,900 shares. | SEC filing Filed Sep 11, 2026 |
| Aug 28, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 679 shares at $20.00 ($14K), marked as a 10b5-1 plan trade. Holdings down 1% to 51,776 shares. | SEC filing Filed Sep 1, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 1,000 shares at $20.00 ($20K), marked as a 10b5-1 plan trade. Holdings down 2% to 51,776 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 17–18, 2026 | Planned (10b5-1) | Christopher Ryan Sullivan (CFO) sold 72,725 shares between Aug 17 and Aug 18 at about $19.94 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 65% to 39,900 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 11, 2026 | Sale | Jennifer Riley (Chief Strategy Officer) sold 2,655 shares at about $19.59 ($52K). Holdings down 7% to 37,041 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 12, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 679 shares at $20.00 ($14K), marked as a 10b5-1 plan trade. Holdings down 1% to 51,776 shares. | SEC filing Filed Aug 12, 2026 |
| Jul 27, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 1,000 shares at $20.00 ($20K), marked as a 10b5-1 plan trade. Holdings down 2% to 51,776 shares. | SEC filing Filed Jul 29, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 4,654 shares at $20.00 ($93K), marked as a 10b5-1 plan trade. Holdings down 8% to 51,776 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 23, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 1,450 shares at $18.00 ($26K), marked as a 10b5-1 plan trade. Holdings down 3% to 51,776 shares. | SEC filing Filed Jun 25, 2026 |
| May 28, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 679 shares at $16.00 ($11K), marked as a 10b5-1 plan trade. Holdings down 1% to 47,122 shares. | SEC filing Filed Jun 1, 2026 |
| May 15, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 3,000 shares at $18.76 ($56K), marked as a 10b5-1 plan trade. Holdings down 45% to 3,622 shares. | SEC filing Filed May 19, 2026 |
| May 7, 2026 | Planned (10b5-1) | Christopher Ryan Sullivan (CFO) sold 18,606 shares at $24.12 ($449K), marked as a 10b5-1 plan trade. Holdings down 98% to 423 shares. | SEC filing Filed May 11, 2026 |
| May 6, 2026 | Planned (10b5-1) | Christopher Ryan Sullivan (CFO) sold 47,000 shares at about $20.18 ($949K), marked as a 10b5-1 plan trade. Holdings down 99% to 423 shares. | SEC filing Filed May 7, 2026 |
| May 6, 2026 | Planned (10b5-1) | Mitchell Chan (Director) sold 3,167 shares at $22.88 ($72K), marked as a 10b5-1 plan trade. Holdings down 50% to 3,166 shares. | SEC filing Filed May 7, 2026 |
| May 6, 2026 | Planned (10b5-1) | Paul Varki (Chief Legal Officer) sold 75,063 shares at about $20.17 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 95% to 3,634 shares. | SEC filing Filed May 7, 2026 |
| May 5–6, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 108,234 shares between May 5 and May 6 at about $20.61 ($2.2M), marked as a 10b5-1 plan trade. Holdings down 97% to 3,622 shares. | SEC filing Filed May 7, 2026 |
| Apr 29–30, 2026 | Planned (10b5-1) | Christopher Ryan Sullivan (CFO) sold 16,915 shares between Apr 29 and Apr 30 at about $13.16 ($223K), marked as a 10b5-1 plan trade. Holdings down 98% to 423 shares. | SEC filing Filed May 1, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 3,970 shares at $18.01 ($71K), marked as a 10b5-1 plan trade. Holdings down 52% to 3,622 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 679 shares at $16.00 ($11K), marked as a 10b5-1 plan trade. Holdings down 16% to 3,622 shares. | SEC filing Filed Apr 3, 2026 |
| Apr 1–2, 2026 | Planned (10b5-1) | Christopher Ryan Sullivan (CFO) sold 15,959 shares between Apr 1 and Apr 2 at about $16.96 ($271K), marked as a 10b5-1 plan trade. Holdings down 48% to 17,338 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Mittie Doyle (Chief Medical Officer) sold 25,492 shares at $16.15 ($412K), marked as a 10b5-1 plan trade. Holdings down 88% to 3,622 shares. | SEC filing Filed Mar 18, 2026 |
| Nov 14, 2025 | Sale | Jonathan Goldman (Director) sold 11,367 shares at about $14.34 ($163K). Holdings down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 17, 2025 |
62 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow AVTX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.